A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Pfizer
Cancer Research UK
Novartis
Pfizer
Tango Therapeutics, Inc.
Amgen
Cancer Research UK
Ikena Oncology
Institut du Cancer de Montpellier - Val d'Aurelle
Aminex Therapeutics, Inc.
Actuate Therapeutics Inc.
University of Southern California
Memorial Sloan Kettering Cancer Center
Deciphera Pharmaceuticals, LLC
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
Southwest Hospital, China
Shenzhen BinDeBio Ltd.
BBB-Therapeutics B.V.
National Cancer Institute (NCI)
GE Healthcare
INSYS Therapeutics Inc
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Thallion Pharmaceuticals